Načítá se...
Spotlight on vismodegib in the treatment of basal cell carcinoma: an evidence-based review of its place in therapy
Vismodegib is approved for the treatment of adult patients with metastatic (mBCC) or locally advanced basal cell carcinoma (laBCC) that have recurred following surgery or for those who are not good candidates for surgery (risk/benefit ratio is against patient’s benefit, either because of the general...
Uloženo v:
| Vydáno v: | Clin Cosmet Investig Dermatol |
|---|---|
| Hlavní autoři: | , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Dove Medical Press
2017
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5436682/ https://ncbi.nlm.nih.gov/pubmed/28546761 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CCID.S101330 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|